TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Risk Factors for Diabetes Complications in Primary Care
Brief Summary: The purpose of this study is to test an intervention in primary care clinics to improve three risk factors for diabetes complications: glucose control, blood pressure and cholesterol. Subjects in the study will be clinic staff and clinicians, not patients. The intervention is Practice Facilitation. Practice facilitation occurs when a trained facilitator meets with a team of staff and clinicians in each practice over a period of several months. Facilitation meetings create time for learning and reflection by members of the team and improves their communication so that they can adopt and implement a strategy to improve patient care


Options:
A: Arm Label: Early implementation practices; Type: ACTIVE_COMPARATOR; Interventions: Other: Implementation of the MOHR assessment in primary care workflow | Arm Label: Delayed implementation practices; Type: OTHER; Interventions: Other: Implementation of the MOHR assessment in primary care workflow | Intervention Type: OTHER; Name: Implementation of the MOHR assessment in primary care workflow; Assigned to Arm(s): Delayed implementation practices, Early implementation practices
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Primary Health Care Model (PRMHLTH) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Recreation Coordination Model (REC) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Comprehensive Model (COMP) | Intervention Type: BEHAVIORAL; Name: Primary Health Care Model (PRMHLTH); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Recreation Coordination Model (REC); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Comprehensive Model (COMP); Assigned to Arm(s): 3
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Practice Facilitation | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Practice Facilitation; Assigned to Arm(s): 1
D: Arm Label: Education-only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy Lifestyles Clinic | Arm Label: Bull City Fit Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Bull City Healthy and Fit | Intervention Type: BEHAVIORAL; Name: Bull City Healthy and Fit; Assigned to Arm(s): Bull City Fit Intervention | Intervention Type: BEHAVIORAL; Name: Healthy Lifestyles Clinic; Assigned to Arm(s): Education-only

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin
Brief Summary: The randomized controlled trial is conducted among antiretroviral naive co-infected HIV and tuberculosis patients who receiving rifampicin-based antituberculous regimen fro at least 4 weeks butt not exceed 16 weeks before enrolment. All patients receive the same backbone regimen of stavudine (30 mg/40 mg twice daily)+ lamivudie 150 mg twice daily. They are randomized to receive nevirapine 400 mg/day twice daily vs efavirenz 600 mg/day at bed time. All patients are followed through 144 weeks after initiation of antiviral therapy. The primary objective are to compare the proportion of patient who achieve undetectable plasma HIV-1RNA\<50 copies/ml at week 48. The previous reports demonstrated that the standard doses of both nevirapine and efavirenz coulde be used among co-infected HIV and tuberculosis patients who receiving rifampicin even though plasma levels are somewhat reduced by rifampicin. However, there have been not been a randomized control trial to compare these two regimens. Thus, this trial will provide the efficacy data between these two regimens.


Options:
A: Arm Label: Efavirenz; Type: EXPERIMENTAL; Interventions: Drug: efavirenz | Arm Label: Nevirapine; Type: EXPERIMENTAL; Interventions: Drug: nevirapine | Intervention Type: DRUG; Name: efavirenz; Assigned to Arm(s): Efavirenz | Intervention Type: DRUG; Name: nevirapine; Assigned to Arm(s): Nevirapine
B: Arm Label: Intervention 2: Nevirapine; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: Intervention 2: Efavirenz; Type: ACTIVE_COMPARATOR; Interventions: Drug: Efavirenz | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): Intervention 2: Nevirapine | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): Intervention 2: Efavirenz
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine based therapy, Drug: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Efavirenz based therapy, Drug: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z) | Intervention Type: DRUG; Name: Nevirapine based therapy; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Efavirenz based therapy; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z); Assigned to Arm(s): 1, 2
D: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Didanosine, Lamivudine, Nevirapine | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Didanosine, Lamivudine, Efavirenz | Intervention Type: DRUG; Name: Didanosine, Lamivudine, Efavirenz; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Didanosine, Lamivudine, Nevirapine; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)
Brief Summary: Attention deficit with hyperactivity disorder (ADHD) is a very common behavioral problem during childhood. It is estimated that up to 80% of this disorder could be related to genetic factors. The most common treatment for ADHD is psychostimulants. In this study, the researchers investigate the effect of genetic variants in increasing the risk for behaviours pertinent to ADHD or in modulating the response of these behaviours to methylphenidate. Response to methylphenidate is evaluated through a double blind placebo controlled one week study.


Options:
A: Arm Label: Methylphenidate, Dexamphetamine, Placebo; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate, Drug: Placebo, Drug: Dextroamphetamine | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo | Intervention Type: DRUG; Name: Dextroamphetamine; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo
B: Arm Label: Ritalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ritalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ritalin; Assigned to Arm(s): Ritalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) | Arm Label: Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR); Assigned to Arm(s): Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg, Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: BEHAVIORAL; Name: Psychosocial treatment; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Anti-ADHD medication; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Assessment-and-Referral; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)
Brief Summary: Attention deficit with hyperactivity disorder (ADHD) is a very common behavioral problem during childhood. It is estimated that up to 80% of this disorder could be related to genetic factors. The most common treatment for ADHD is psychostimulants. In this study, the researchers investigate the effect of genetic variants in increasing the risk for behaviours pertinent to ADHD or in modulating the response of these behaviours to methylphenidate. Response to methylphenidate is evaluated through a double blind placebo controlled one week study.


Options:
A: Intervention Type: BEHAVIORAL; Name: Pediatric Practice-Based Smoking Intervention; Assigned to Arm(s): N/A
B: Arm Label: Bupropion SR + Contingency Management; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: Contingency Management | Arm Label: Placebo + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management, Other: Placebo | Arm Label: Bupropion SR + No Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo + No Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR + Contingency Management, Bupropion SR + No Contingency Management | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Bupropion SR + Contingency Management, Placebo + Contingency Management | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Contingency Management, Placebo + No Contingency Management
C: Arm Label: Ritalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ritalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ritalin; Assigned to Arm(s): Ritalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational Interviewing (MI) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured Brief Advice (SBA) | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing (MI); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Structured Brief Advice (SBA); Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)
Brief Summary: Attention deficit with hyperactivity disorder (ADHD) is a very common behavioral problem during childhood. It is estimated that up to 80% of this disorder could be related to genetic factors. The most common treatment for ADHD is psychostimulants. In this study, the researchers investigate the effect of genetic variants in increasing the risk for behaviours pertinent to ADHD or in modulating the response of these behaviours to methylphenidate. Response to methylphenidate is evaluated through a double blind placebo controlled one week study.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: clonidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylphenidate | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: clonidine, Drug: methylphenidate | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: clonidine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): 2, 3 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): 4
B: Arm Label: Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) | Arm Label: Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR); Assigned to Arm(s): Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg, Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Cannabis oil high dose; Type: EXPERIMENTAL; Interventions: Drug: Tetrahydrocannabinol | Arm Label: Cannabis oil low dose; Type: EXPERIMENTAL; Interventions: Drug: Tetrahydrocannabinol | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dummy oromucosal | Intervention Type: DRUG; Name: Tetrahydrocannabinol; Assigned to Arm(s): Cannabis oil high dose, Cannabis oil low dose | Intervention Type: DRUG; Name: Dummy oromucosal; Assigned to Arm(s): Control
D: Arm Label: Ritalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ritalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ritalin; Assigned to Arm(s): Ritalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Telephone Follow-Up on Outcome After Mild TBI
Brief Summary: The purpose of this study is to see whether providing education and counseling after a mild traumatic brain injury will help in preventing symptoms from becoming chronic over the first six months after injury.


Options:
A: Arm Label: MBCT Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: MBCT for TBI | Arm Label: MBCT Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MBCT for TBI; Assigned to Arm(s): MBCT Intervention Group
B: Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Scheduled telephone follow-up | Intervention Type: BEHAVIORAL; Name: Scheduled telephone follow-up; Assigned to Arm(s): 1
C: Arm Label: Treatment Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy | Arm Label: Treatment Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Supportive psychotherapy | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy; Assigned to Arm(s): Treatment Arm 1 | Intervention Type: BEHAVIORAL; Name: Supportive psychotherapy; Assigned to Arm(s): Treatment Arm 2
D: Arm Label: Telephone-based CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Cognitive Behavioral Therapy | Arm Label: In-person CBT; Type: EXPERIMENTAL; Interventions: Behavioral: In-person Cognitive Behavioral Therapy | Arm Label: 3: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: In-person Cognitive Behavioral Therapy; Assigned to Arm(s): In-person CBT | Intervention Type: BEHAVIORAL; Name: Telephone Cognitive Behavioral Therapy; Assigned to Arm(s): Telephone-based CBT

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maximizing Opportunity: HIV Prevention in Hospitalized Russian Drinkers
Brief Summary: The objective of this study is to test in a randomized controlled trial the effectiveness of a US secondary HIV prevention program to reduce HIV risk behaviors, STD acquisition, and alcohol consumption among HIV-infected Russians with risky drinking.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Interviewing & Skills Training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Interviewing & Skills Training | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Adapted Motivational Interviewing & Skills Training; Assigned to Arm(s): 1, 2
B: Arm Label: Fruit and Vegetable Intake Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Fruit and vegetable intake in rural youth | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Fruit and vegetable intake in rural youth; Assigned to Arm(s): Fruit and Vegetable Intake Behavioral Intervention
C: Intervention Type: BEHAVIORAL; Name: Collaborative Behavioral Management; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Integrated parole and outpatient addiction treatment; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Individual and group HIV risk behavior counseling sessions | Arm Label: Attention-control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: health education and support group | Intervention Type: BEHAVIORAL; Name: Individual and group HIV risk behavior counseling sessions; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: health education and support group; Assigned to Arm(s): Attention-control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renal Denervation in Patients With Refractory Hypertension
Brief Summary: To investigate the clinical utility of renal denervation in the treatment of refractory hypertension.


Options:
A: Arm Label: Denervation; Type: EXPERIMENTAL; Interventions: Device: Ardian Symplicity™ Catheter | Intervention Type: DEVICE; Name: Ardian Symplicity™ Catheter; Assigned to Arm(s): Denervation
B: Arm Label: renal sympathetic denervation; Type: EXPERIMENTAL; Interventions: Procedure: renal sympathetic denervation, Drug: drug, Procedure: Direct-Current Cardioversion | Arm Label: drug therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: drug | Intervention Type: PROCEDURE; Name: renal sympathetic denervation; Assigned to Arm(s): renal sympathetic denervation | Intervention Type: DRUG; Name: drug; Assigned to Arm(s): drug therapy, renal sympathetic denervation | Intervention Type: PROCEDURE; Name: Direct-Current Cardioversion; Assigned to Arm(s): renal sympathetic denervation
C: Arm Label: Renal sympathetic denervation; Type: EXPERIMENTAL; Interventions: Device: Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA) | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Other: Sham procedure | Intervention Type: DEVICE; Name: Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA); Assigned to Arm(s): Renal sympathetic denervation | Intervention Type: OTHER; Name: Sham procedure; Assigned to Arm(s): Sham procedure
D: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Device: Boston Scientific Vessix Renal Denervation System | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Boston Scientific Vessix Renal Denervation System; Assigned to Arm(s): Intervention arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renal Denervation in Patients With Refractory Hypertension
Brief Summary: To investigate the clinical utility of renal denervation in the treatment of refractory hypertension.


Options:
A: Arm Label: Renal denervation; Type: N/A; Interventions: Device: Renal denervation using Symplicity Catheter system | Intervention Type: DEVICE; Name: Renal denervation using Symplicity Catheter system; Assigned to Arm(s): Renal denervation
B: Arm Label: Renal sympathetic denervation; Type: EXPERIMENTAL; Interventions: Device: Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA) | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Other: Sham procedure | Intervention Type: DEVICE; Name: Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA); Assigned to Arm(s): Renal sympathetic denervation | Intervention Type: OTHER; Name: Sham procedure; Assigned to Arm(s): Sham procedure
C: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Device: Boston Scientific Vessix Renal Denervation System | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Boston Scientific Vessix Renal Denervation System; Assigned to Arm(s): Intervention arm
D: Arm Label: Denervation; Type: EXPERIMENTAL; Interventions: Device: Ardian Symplicity™ Catheter | Intervention Type: DEVICE; Name: Ardian Symplicity™ Catheter; Assigned to Arm(s): Denervation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Prucalopride (R108512) Tablets in Subjects With Chronic Constipation.
Brief Summary: The purpose of this study is to determine whether prucalopride is safe and effective in the treatment of chronic constipation.

Hypothesis:

Prucalopride 2 mg and 4 mg given once daily for 12 weeks is superior to placebo for the treatment of patients with chronic constipation and is well tolerated in those patients.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 4
B: Arm Label: 72 ug linaclotide acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: linaclotide acetate | Arm Label: 145 ug linaclotide acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: linaclotide acetate | Arm Label: 290 ug linaclotide acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: linaclotide acetate | Arm Label: 579 ug linaclotide acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: linaclotide acetate | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: linaclotide acetate; Assigned to Arm(s): 145 ug linaclotide acetate, 290 ug linaclotide acetate, 579 ug linaclotide acetate, 72 ug linaclotide acetate | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): Matching Placebo
C: Arm Label: A3309 15 mg; Type: EXPERIMENTAL; Interventions: Drug: A3309 | Arm Label: A3309 20 mg; Type: EXPERIMENTAL; Interventions: Drug: A3309 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: A3309; Assigned to Arm(s): A3309 15 mg, A3309 20 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 2

Answer: D